blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3116902

EP3116902 - METHOD FOR GENERATING T-CELLS COMPATIBLE FOR ALLOGENIC TRANSPLANTATION [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  24.01.2025
Database last updated on 31.03.2026
FormerThe patent has been granted
Status updated on  05.12.2019
FormerGrant of patent is intended
Status updated on  21.08.2019
FormerExamination is in progress
Status updated on  07.07.2017
FormerRequest for examination was made
Status updated on  16.12.2016
FormerThe international publication has been made
Status updated on  09.11.2016
Most recent event   Tooltip24.01.2025Revocation of patentpublished on 26.02.2025  [2025/09]
Applicant(s)For all designated states
Cellectis
8, rue de la Croix Jarry
75013 Paris / FR
[2017/03]
Inventor(s)01 / POIROT, Laurent
10 rue de la réunion
F-75020 Paris / FR
02 / SOURDIVE, David
19 Rue Louise Michel
F-92300 Levallois-Perret / FR
03 / DUCHATEAU, Philippe
Bateau Fawen Quai des Dames
F-91210 Draveil / FR
04 / CABANIOLS, Jean-Pierre
17 rue des églantines
F-95320 Saint Lau la Forêt / FR
 [2020/01]
Former [2017/03]01 / POIROT, Laurent
10 rue de la réunion
F-75020 Paris / FR
02 / SOURDIVE, David
19 Rue Louise Michel
F-92300 Levallois-Perret / FR
03 / DUCHATEAU, Philippe
Bateau Fawen Quai des Dames
F-91210 Draveil / FR
04 / CABANIOLS, Jean-Pierre
17 Rue des Églantines
F-95320 Saint Lau la Forêt / FR
Representative(s)Ernest Gutmann - Yves Plasseraud S.A.S.
C/o Plasseraud IP
104 Rue de Richelieu
CS 92104
75080 Paris Cedex 02 / FR
[N/P]
Former [2017/03]Zacco Denmark A/S
Arne Jacobsens Allé 15
2300 Copenhagen S / DK
Application number, filing date15709185.111.03.2015
[2017/03]
WO2015EP55097
Priority number, dateDK2014007011911.03.2014         Original published format: DK 201470119
[2017/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015136001
Date:17.09.2015
Language:EN
[2015/37]
Type: A1 Application with search report 
No.:EP3116902
Date:18.01.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 17.09.2015 takes the place of the publication of the European patent application.
[2017/03]
Type: B1 Patent specification 
No.:EP3116902
Date:01.01.2020
Language:EN
[2020/01]
Search report(s)International search report - published on:EP17.09.2015
ClassificationIPC:C07K14/74, C12N5/0783
[2017/03]
CPC:
A61P31/12 (EP,IL); C12N5/0636 (EP,IL,KR,RU,US); A61K35/17 (EP,IL,KR,RU,US);
C12N15/85 (IL,RU,US); A61K35/28 (IL); A61K39/0011 (EP,IL,KR,RU,US);
A61P35/00 (EP,IL,RU); A61P35/02 (EP,IL,RU); C07K14/705 (RU);
C07K14/70503 (IL,US); C07K14/70539 (EP,IL,KR,US); C12N15/1138 (IL,RU,US);
C12N15/907 (IL,US); A61K2039/5156 (EP,IL,KR,RU,US); A61K2039/5158 (EP,IL,KR,RU,US);
C07K14/7051 (EP); C07K2317/24 (IL,US); C07K2317/622 (IL,US);
C07K2319/03 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/03]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:VERFAHREN ZUR ERZEUGUNG VON T-ZELLEN MIT KOMPATIBILITÄT FÜR ALLOGENE TRANSPLANTATION[2017/03]
English:METHOD FOR GENERATING T-CELLS COMPATIBLE FOR ALLOGENIC TRANSPLANTATION[2017/03]
French:PROCÉDÉ D'OBTENTION DE LYMPHOCYTES T COMPATIBLES AVEC LA TRANSPLANTATION ALLOGÉNIQUE[2017/03]
Entry into regional phase07.10.2016National basic fee paid 
07.10.2016Designation fee(s) paid 
07.10.2016Examination fee paid 
Examination procedure07.10.2016Amendment by applicant (claims and/or description)
07.10.2016Examination requested  [2017/03]
07.10.2016Date on which the examining division has become responsible
05.07.2017Despatch of a communication from the examining division (Time limit: M06)
11.01.2018Reply to a communication from the examining division
13.02.2018Despatch of a communication from the examining division (Time limit: M06)
19.09.2018Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
08.11.2018Reply to a communication from the examining division
23.11.2018Despatch of a communication from the examining division (Time limit: M06)
29.05.2019Reply to a communication from the examining division
11.07.2019Despatch of a communication from the examining division (Time limit: M04)
12.07.2019Reply to a communication from the examining division
22.08.2019Communication of intention to grant the patent
20.11.2019Fee for grant paid
20.11.2019Fee for publishing/printing paid
20.11.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19219954.5  / EP3693384
EP24153261.3  / EP4368705
Opposition(s)Opponent(s)01  01.10.2020  05.10.2020  ADMISSIBLE
Weinzierl, Gerhard
Schiweck Weinzierl Koch
Patentanwälte Partnerschaft mbB
Ganghoferstraße 68B
80339 München / DE
Opponent's representative
Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB
Ganghoferstraße 68 B
80339 München / DE
 02  01.10.2020  05.10.2020  ADMISSIBLE
CENTURY THERAPEUTICS, LLC
3675 Market Street
Philadelphia, PA 19104 / US
Opponent's representative
Carpmaels & Ransford LLP, et al, et al
One Southampton Row
London WC1B 5HA / GB
 03  01.10.2020  05.10.2020  ADMISSIBLE
James Poole Limited
One Southampton Row
London WC1B 5HA / GB
Opponent's representative
Carpmaels & Ransford LLP, et al, et al
One Southampton Row
London WC1B 5HA / GB
 04  01.10.2020  05.10.2020  ADMISSIBLE
European Oppositions Limited
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
Opponent's representative
Lee, Nicholas John, et al, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
 [2021/37]
Former [2020/46]
Opponent(s)01  01.10.2020  05.10.2020  ADMISSIBLE
Weinzierl, Gerhard
Schiweck Weinzierl Koch
Patentanwälte Partnerschaft mbB
Ganghoferstraße 68B
80339 München / DE
Opponent's representative
Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB
Ganghoferstraße 68 B
80339 München / DE
 02  01.10.2020  05.10.2020  ADMISSIBLE
CENTURY THERAPEUTICS, LLC
3675 Market Street
Philadelphia, PA 19104 / US
Opponent's representative
Goodfellow, Hugh Robin, et al, et al
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
 03  01.10.2020  05.10.2020  ADMISSIBLE
James Poole Limited
One Southampton Row
London WC1B 5HA / GB
Opponent's representative
Duffield, Stephen, et al, et al
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
 04  01.10.2020  05.10.2020  ADMISSIBLE
European Oppositions Limited
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
Opponent's representative
Lee, Nicholas John, et al, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
Former [2020/45]
Opponent(s)01  01.10.2020   
Weinzierl, Gerhard
Schiweck Weinzierl Koch
Patentanwälte Partnerschaft mbB
Ganghoferstraße 68B
80339 München / DE
Opponent's representative
Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB
Ganghoferstraße 68 B
80339 München / DE
13.10.2020Invitation to proprietor to file observations on the notice of opposition
23.02.2021Reply of patent proprietor to notice(s) of opposition
22.06.2022Date of oral proceedings
22.09.2022Despatch of minutes of oral proceedings
22.09.2022Despatch of communication that the patent will be revoked
19.12.2024Legal effect of revocation of patent [2025/09]
Appeal following opposition22.11.2022Appeal received No.  T2494/22
22.11.2022Payment of appeal fee
02.02.2023Statement of grounds filed
19.12.2024Result of appeal procedure: appeal of the proprietor withdrawn
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
08.11.2018Request for further processing filed
08.11.2018Full payment received (date of receipt of payment)
Request granted
19.11.2018Decision despatched
Fees paidRenewal fee
10.03.2017Renewal fee patent year 03
13.03.2018Renewal fee patent year 04
13.03.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL01.01.2020
CY01.01.2020
CZ01.01.2020
EE01.01.2020
FI01.01.2020
HR01.01.2020
LT01.01.2020
LV01.01.2020
MC01.01.2020
MK01.01.2020
MT01.01.2020
RO01.01.2020
RS01.01.2020
SI01.01.2020
SK01.01.2020
SM01.01.2020
LU11.03.2020
GR02.04.2020
IS01.05.2020
[2022/31]
Former [2022/28]CY01.01.2020
CZ01.01.2020
EE01.01.2020
FI01.01.2020
HR01.01.2020
LT01.01.2020
LV01.01.2020
MC01.01.2020
MT01.01.2020
RO01.01.2020
RS01.01.2020
SI01.01.2020
SK01.01.2020
SM01.01.2020
LU11.03.2020
GR02.04.2020
IS01.05.2020
Former [2021/13]CZ01.01.2020
EE01.01.2020
FI01.01.2020
HR01.01.2020
LT01.01.2020
LV01.01.2020
MC01.01.2020
RO01.01.2020
RS01.01.2020
SI01.01.2020
SK01.01.2020
SM01.01.2020
LU11.03.2020
GR02.04.2020
IS01.05.2020
Former [2021/04]CZ01.01.2020
EE01.01.2020
FI01.01.2020
HR01.01.2020
LT01.01.2020
LV01.01.2020
MC01.01.2020
RO01.01.2020
RS01.01.2020
SK01.01.2020
SM01.01.2020
LU11.03.2020
GR02.04.2020
IS01.05.2020
Former [2020/50]CZ01.01.2020
EE01.01.2020
FI01.01.2020
HR01.01.2020
LT01.01.2020
LV01.01.2020
MC01.01.2020
RO01.01.2020
RS01.01.2020
SK01.01.2020
SM01.01.2020
GR02.04.2020
IS01.05.2020
Former [2020/49]CZ01.01.2020
FI01.01.2020
HR01.01.2020
LT01.01.2020
LV01.01.2020
MC01.01.2020
RO01.01.2020
RS01.01.2020
SK01.01.2020
SM01.01.2020
GR02.04.2020
IS01.05.2020
Former [2020/48]CZ01.01.2020
FI01.01.2020
HR01.01.2020
LT01.01.2020
LV01.01.2020
RO01.01.2020
RS01.01.2020
SM01.01.2020
GR02.04.2020
IS01.05.2020
Former [2020/40]CZ01.01.2020
FI01.01.2020
HR01.01.2020
LT01.01.2020
LV01.01.2020
RS01.01.2020
GR02.04.2020
IS01.05.2020
Former [2020/38]CZ01.01.2020
FI01.01.2020
HR01.01.2020
LT01.01.2020
LV01.01.2020
RS01.01.2020
GR02.04.2020
Former [2020/37]CZ01.01.2020
FI01.01.2020
HR01.01.2020
LT01.01.2020
LV01.01.2020
RS01.01.2020
Former [2020/35]CZ01.01.2020
FI01.01.2020
LT01.01.2020
Cited inInternational search[Y] WO2013158292  (UNIV WASHINGTON CT COMMERCIALI et al.) [Y] 1-59 * paragraph [0063] - paragraph [0064]; claims 1, 9 *
 [Y] WO9517911  (CELL GENESYS INC et al.) [Y] 1-59 * page 22 - page 23 * * page 33, paragraph 1 * * page 6, line 19 - line 32 * * page 10 - page 11 *
 [Y] WO9302188  (OKLAHOMA MED RES FOUND et al.) [Y] 1-59 * page 26, line 14 - page 29, line 7; claims 2, 15 *
 [Y] WO2013049459  (STEMBIOS TECHNOLOGIES INC et al.) [Y] 1-59 * page 18, line 16 - line 20 *
 [Y] US2006222633  (SHLOMCHIK WARREN D et al.) [Y] 1-59 * paragraph [0042]; figure 7; examples 3, 4 *
 [Y] WO2008102274  (CELLECTIS et al.) [Y] 1-59 * page 26, line 11 - page 27, line 29; claims 1-41 *
 [Y] WO2005097160  (UNIV CALIFORNIA et al.) [Y] 15-20,46-51 * example 6; claims 1-44 *
 [Y]   V. TRICHET ET AL: "Complex Interplay of Activating and Inhibitory Signals Received by V 9V 2 T Cells Revealed by Target Cell 2-Microglobulin Knockdown", THE JOURNAL OF IMMUNOLOGY, vol. 177, no. 9, 18 October 2006 (2006-10-18), pages 6129 - 6136, XP055145651, ISSN: 0022-1767, DOI: 10.4049/jimmunol.177.9.6129 [Y] 1-59 * the whole document *

DOI:   http://dx.doi.org/10.4049/jimmunol.177.9.6129
 [Y]   DAMMEYER P ET AL: "Vaccination with beta(2)-Microglobulin-Deficient Dendritic Cells Protects Against Growth of beta(2)-Microglobulin-Deficient Tumours", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, BLACKWELL SCIENCE PUBL., OXFORD, GB, vol. 70, no. 1, 25 April 2009 (2009-04-25), pages 44 - 52, XP002544734, ISSN: 0300-9475, [retrieved on 20090425], DOI: 10.1111/J.1365-3083.2009.02270.X [Y] 1-59 * the whole document * * page 45, column l *

DOI:   http://dx.doi.org/10.1111/J.1365-3083.2009.02270.X
 [Y]   Y. MATSUNAGA ET AL: "Activation of Antigen-Specific Cytotoxic T Lymphocytes by 2-Microglobulin or TAP1 Gene Disruption and the Introduction of Recipient-Matched MHC Class I Gene in Allogeneic Embryonic Stem Cell-Derived Dendritic Cells", THE JOURNAL OF IMMUNOLOGY, vol. 181, no. 9, 20 October 2008 (2008-10-20), pages 6635 - 6643, XP055145645, ISSN: 0022-1767, DOI: 10.4049/jimmunol.181.9.6635 [Y] 1-59 * the whole document * * abstract *

DOI:   http://dx.doi.org/10.4049/jimmunol.181.9.6635
 [Y]   LAURA RIOLOBOS ET AL: "HLA Engineering of Human Pluripotent Stem Cells", MOLECULAR THERAPY, vol. 21, no. 6, 30 April 2013 (2013-04-30), pages 1232 - 1241, XP055145726, ISSN: 1525-0016, DOI: 10.1038/mt.2013.59 [Y] 1-59 * the whole document * * page 1237, column r *

DOI:   http://dx.doi.org/10.1038/mt.2013.59
 [Y]   P. HOGLUND ET AL: "Recognition of beta 2-microglobulin-negative (beta 2m-) T-cell blasts by natural killer cells from normal but not from beta 2m- mice: nonresponsiveness controlled by beta 2m- bone marrow in chimeric mice.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 88, no. 22, 15 November 1991 (1991-11-15), pages 10332 - 10336, XP055145720, ISSN: 0027-8424, DOI: 10.1073/pnas.88.22.10332 [Y] 1-59 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.88.22.10332
 [Y]   HOLLING T M ET AL: "Epigenetic silencing of MHC2TA transcription in cancer", BIOCHEMICAL PHARMACOLOGY, ELSEVIER, US, vol. 72, no. 11, 30 November 2006 (2006-11-30), pages 1570 - 1576, XP027905310, ISSN: 0006-2952, [retrieved on 20061130] [Y] 1-59 * the whole document *
 [Y]   GAJ THOMAS ET AL: "ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 31, no. 7, 9 May 2013 (2013-05-09), pages 397 - 405, XP028571313, ISSN: 0167-7799, DOI: 10.1016/J.TIBTECH.2013.04.004 [Y] 1-7,10,24-36,40,41 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.tibtech.2013.04.004
 [Y]   AGNIESZKA WIECZOREK ET AL: "Genetically Modified T Cells for the Treatment of Malignant Disease", TRANSFUSION MEDICINE AND HEMOTHERAPY, vol. 40, no. 6, 29 November 2013 (2013-11-29), pages 388 - 402, XP055145975, ISSN: 1660-3796, DOI: 10.1159/000357163 [Y] 38-48 * the whole document *

DOI:   http://dx.doi.org/10.1159/000357163
 [Y]   MELISA A. SOLAND ET AL: "Modulation of Human Mesenchymal Stem Cell Immunogenicity through Forced Expression of Human Cytomegalovirus US Proteins", PLOS ONE, vol. 7, no. 5, 30 May 2012 (2012-05-30), pages e36163, XP055187588, DOI: 10.1371/journal.pone.0036163 [Y] 15-20,46-51 * the whole document *

DOI:   http://dx.doi.org/10.1371/journal.pone.0036163
ExaminationWO2014165825
 WO2014165707
 WO2013176915
   SHU SU ET AL: "CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients", SCIENTIFIC REPORTS, vol. 6, 28 January 2016 (2016-01-28), pages 20070, XP055267477, DOI: 10.1038/srep20070 [T]

DOI:   http://dx.doi.org/10.1038/srep20070
OppositionWO2013074916
 WO2013176915
 WO2008102274
 WO2012145384
 WO2013158292
 EP2015055097
 WO2014165707
 WO2013176915
 WO2008102274
 WO2012145384
 WO2013158292
 WO9517911
 WO2005097160
 WO2014159435
 WO2014165707
 WO2013074916
 WO2014138315
 WO2008102274
 WO2012138927
 WO2013176915
 US2007036773
 WO2009141729
 WO2013158292
 WO9517911
 WO2008102274
 WO2013049459
 US2006222633
 WO9302188
 WO2014165707
   TORIKAI ET AL.: "A foundation for universal T- cell based immunotherapy: T cells engineered to express a CD 19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR", BLOOD, vol. 119, 2012, pages 5697 - 5705, XP055546827, DOI: 10.1182/blood-2012-01-405365

DOI:   http://dx.doi.org/10.1182/blood-2012-01-405365
   CARROLL: "A CRISPR Approach to Gene Targeting", MOLECULAR THERAPY, vol. 20, 2012, pages 1658 - 1660, XP055106489, DOI: 10.1038/mt.2012.171

DOI:   http://dx.doi.org/10.1038/mt.2012.171
   RIOLOBOS ET AL.: "HLA Engineering of Human Pluripotent Stem Cells", MOLECULAR THERAPY, vol. 21, 2013, pages 1232 - 1241, XP055145726, DOI: 10.1038/mt.2013.59

DOI:   http://dx.doi.org/10.1038/mt.2013.59
   LE ET AL.: "CIITA Transformation Rescues the Apoptotic Function of MHC Class II in Melanoma Cells", ANTICANCER RESEARCH, vol. 25, November 2005 (2005-11-01), pages 3889 - 3892, XP055738560
   LLOYD ET AL.: "Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies", FRONTIERS IN IMMUNOLOGY, vol. 4, 221, 5 August 2013 (2013-08-05), pages 1 - 7, XP055110101, DOI: 10.3389/fimmu.2013.00221

DOI:   http://dx.doi.org/10.3389/fimmu.2013.00221
   JOHN ET AL.: "Blockade of PD-1 immunosuppression boosts CAR T- cell therapy", ONCOIMMUNOLOGY, vol. 2, no. 10, 10 October 2013 (2013-10-10), pages e26286, XP055302338, DOI: 10.4161/onci.26286

DOI:   http://dx.doi.org/10.4161/onci.26286
   KIM ET AL.: "Human Cytomegalovirus UL18 Utilizes US 6 for Evading the NK and T- Cell Responses", PLOS PATHOGENC, vol. 4, no. 8, 8 August 2008 (2008-08-08), pages e1000123, XP055738561

DOI:   http://dx.doi.org/10.1371/journal.ppat.1000123
   MASTERNAK ET AL.: "CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex", GENES & DEVELOPMENT, vol. 14, no. 9, 1 May 2000 (2000-05-01), pages 1156 - 1166, XP055738563

DOI:   http://dx.doi.org/10.1101/gad.14.9.1156
   SALIH ET AL.: "Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia", BLOOD, vol. 102, 2003, pages 1389 - 1396, XP002360664
   WIECZOREK ET AL.: "Genetically Modified T Cells for the Treatment of Malignant Disease", TRANSFUS MED HEMOTHER, vol. 40, 2013, pages 388 - 402, XP055145975, DOI: 10.1159/000357163

DOI:   http://dx.doi.org/10.1159/000357163
   THOMAS ET AL.: "ZFN, TALEN and CRISPR/Cas-based methods for genome engineering", TRENDS BIOTECHNO, vol. 31, no. 7, 9 May 2013 (2013-05-09), pages 397 - 405, XP028571313

DOI:   http://dx.doi.org/10.1016/j.tibtech.2013.04.004
   SOLAND ET AL.: "Modulation of Human Mesenchymal Stem Cell Immunogenicity through Forced Expression of Human Cytomegalovirus US Proteins", PLOS ONE, vol. 7, no. 5, 2012, pages e36163, XP055187588, DOI: 10.1371/journal.pone.0036163

DOI:   http://dx.doi.org/10.1371/journal.pone.0036163
   RIOLOBOS ET AL.: "HLA Engineering of Human Pluripotent Stem Cells", MOL THER, vol. 21, no. 6, 2013, pages 1232 - 41, XP055145726, DOI: 10.1038/mt.2013.59

DOI:   http://dx.doi.org/10.1038/mt.2013.59
   MACH B. ET AL.: "MHC Class II-Deficient Combined Immunodeficiency: A Disease of Gene Regulation", IMMUNOLOGICAL REVIEWS, vol. 138, no. 1, 1 April 1994 (1994-04-01), pages 207 - 221, XP055738777
   BIX ET AL.: "Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice", NATURE, vol. 349, no. 6307, 1 January 1991 (1991-01-01), pages 329 - 331, XP002389150

DOI:   http://dx.doi.org/10.1038/349329a0
   RIOLOBOS ET AL.: "HLA Engineering of Human Pluripotent Stem Cells", MOLECULAR THERAPY, vol. 21, no. 6, 1 June 2013 (2013-06-01), pages 1232 - 1241, XP055145726

DOI:   http://dx.doi.org/10.1038/mt.2013.59
   FIGUEIREDO C. ET AL.: "Regulating MHC expression for cellular therapeutics", TRANSFUSION, vol. 47, no. 1, 1 January 2007 (2007-01-01), pages 18 - 27, XP055738565

DOI:   http://dx.doi.org/10.1111/j.1537-2995.2007.01059.x
   LU P. ET AL.: "Generating Hypoimmunogenic Human Embryonic Stem Cells by the Disruption of Beta 2-Microglobulin", STEM CELL REV AND REP, vol. 9, no. 6, 10 August 2013 (2013-08-10), pages 806 - 813, XP055560204, DOI: 10.1007/s12015-013-9457-0

DOI:   http://dx.doi.org/10.1007/s12015-013-9457-0
   MEISSNER ET AL.: "Genome editing for human gene therapy", METHODS IN ENZYMOLOGY, vol. 546, 1 January 2014 (2014-01-01), pages 273 - 295, XP008179752

DOI:   http://dx.doi.org/10.1016/B978-0-12-801185-0.00013-1
   TORIKAI ET AL.: "Engineering in Translational Medicine", 20 December 2013, SPRINGER, article "Engineering T cells to target tumor cells", pages: 71 - 101, XP055738567

DOI:   http://dx.doi.org/10.1007/978-1-4471-4372-7_3
   THEMELI ET AL.: "Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy", NAT. BIOTECH, vol. 31, no. 10, 11 August 2013 (2013-08-11), pages 928 - 933, XP055485171

DOI:   http://dx.doi.org/10.1038/nbt.2678
   PROVASI ET AL.: "Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer", NATURE MEDICINE, vol. 18, no. 5, 1 April 2012 (2012-04-01), pages 807 - 817, XP055181611

DOI:   http://dx.doi.org/10.1038/nm.2700
   GAJ ET AL.: "ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering", TRENDS IN BIOTECHNOLOGY, vol. 31, no. 7, 9 May 2013 (2013-05-09), pages 397 - 405, XP028571313

DOI:   http://dx.doi.org/10.1016/j.tibtech.2013.04.004
   SCHARENBERG A. ET AL: "Genome Engineering with TAL-Effector Nucleases and Alternative Modular Nuclease Technologies", CURRENT GENE THERAPY, vol. 13, no. 4, 1 September 2013 (2013-09-01), pages 291 - 303, XP055385972

DOI:   http://dx.doi.org/10.2174/15665232113139990026
   ANONYMOUS: "Cellectis bioresearch launches Compact TALEN the next generation of TAL effector nucleases", CELLECTIS PRESS RELEASE, 23 September 2013 (2013-09-23), XP055738574, Retrieved from the Internet
   BEURDELEY ET AL.: "Compact designer TALENs for efficient genome engineering", NATURE COMMUNICATIONS, vol. 4, 23 April 2013 (2013-04-23), pages 1 - 8, XP055073282

DOI:   http://dx.doi.org/10.1038/ncomms2782
   JOHN ET AL.: "Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells", CLIN CANCER RES, vol. 19, no. 20, 19 July 2013 (2013-07-19), pages 5636 - 5646, XP002737460

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-13-0458
   REYBURN H. ET AL.: "The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells", NATURE, vol. 386, no. 6624, April 1997 (1997-04-01), pages 514 - 517, XP055738570

DOI:   http://dx.doi.org/10.1038/386514a0
   WILKINSON ET AL.: "Modulation of natural killer cells by human cytomegalovirus", J CLIN VIROL, vol. 41, no. 3, 15 February 2008 (2008-02-15), pages 206 - 12, XP022483244

DOI:   http://dx.doi.org/10.1016/j.jcv.2007.10.027
   CAMPOLI ET AL.: "Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands", TISSUE ANTIGEN, vol. 72, no. 4, 1 October 2008 (2008-10-01), pages 321 - 34, XP055738571

DOI:   http://dx.doi.org/10.1111/j.1399-0039.2008.01106.x
   GONZALEZ ET AL.: "Amplification of RNAiTargeting HLA mRNA", MOL THER, vol. 11, no. 5, 1 May 2005 (2005-05-01), pages 811 - 888, XP004863188

DOI:   http://dx.doi.org/10.1016/j.ymthe.2004.12.023
   REN ET AL.: "Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition", CLIN CANCER RES, vol. 23, no. 9, 11 April 2017 (2017-04-11), pages 2255 - 2266, XP055565027

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-16-1300
   TRICHET V. ET AL.: "Complex Interplay of Activating and Inhibitory Signals Received by V y9V62 T Cells Revealed by Target Cell P2 -Microglobulin Knockdown", JOURNAL IMMUNOLOGY, vol. 177, no. 9, 18 October 2006 (2006-10-18), pages 6129 - 6136, XP055145651

DOI:   http://dx.doi.org/10.4049/jimmunol.177.9.6129
   DAMMEYER ET AL.: "Vaccination with beta2-Microglobulin-Deficient Dendritic Cells Protects Against Growth of beta2-Microglobulin-Deficient Tumours", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 70, no. 1, July 2009 (2009-07-01), pages 44 - 52, XP002544734

DOI:   http://dx.doi.org/10.1111/J.1365-3083.2009.02270.X
   MATSUNAGA ET AL.: "Activation of Antigen-Specific Cytotoxic T Lymphocytes by 2-Microglobulin or TAP1 Gene Disruption and the Introduction of Recipient-Matched MHC Class I Gene in Allogeneic Embryonic Stem Cell-Derived Dendritic Cells", JOURNAL IMMUNOLOGY, vol. 181, no. 9, 20 October 2008 (2008-10-20), pages 6635 - 6643, XP055145645

DOI:   http://dx.doi.org/10.4049/jimmunol.181.9.6635
   RIOLOBOS ET AL.: "HLA Engineering of Human Pluripotent Stem Cells", MOLECULAR THERAPY, vol. 21, 2013, pages 1232 - 1241, XP055145726, DOI: 10.1038/mt.2013.59

DOI:   http://dx.doi.org/10.1038/mt.2013.59
   GAJ ET AL.: "ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering", TRENDS IN BIOTECHNOLOGY, vol. 31, no. 7, July 2013 (2013-07-01), pages 397 - 405, XP028571313

DOI:   http://dx.doi.org/10.1016/j.tibtech.2013.04.004
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.